GlassScriptPhysician profile
Twinkle A Myint
NPI 1003807447
$5,244.74
in general payments reported to CMS, 2019-2025
36 companies · $31.22 in 2025
The $31.22 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,564 · 2020: $1,383 · 2021: $1,084 · 2022: $605 · 2023: $403 · 2024: $174 · 2025: $31.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $593 · Education: $15.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $593.38 |
| Education | $15.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $590.32 | 2019-2023 | Ozempic, Rybelsus |
| Abbvie INC. | $547.38 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $530.00 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $447.97 | 2019-2024 | Airsupra |
| Glaxosmithkline, LLC. | $429.03 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $401.75 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $274.80 | 2019-2021 | |
| Pfizer INC. | $260.70 | 2019-2023 | |
| Astellas Pharma US INC | $175.27 | 2019-2024 | Veozah |
| Allergan, INC. | $164.32 | 2019-2020 | |
| Lilly USA, LLC | $161.72 | 2019-2024 | Jardiance, Emgality, Mounjaro |
| Abbott Laboratories | $138.48 | 2019-2024 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $114.20 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $113.60 | 2021-2024 | |
| Amarin Pharma, INC. | $110.73 | 2019-2020 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Twinkle Myint listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.